Table II.

Biomarker levels at baseline and after treatment with simvastatin (day 21) in low-dose (20 mg/d), moderate-dose (40 mg/d) and combined groups.

	Low-dose, 20 mg/d (n = 14)			Moderate dose, 40 mg/d (n = 12)			Combined group (n = 26)
	Baseline	Day 21	P-value	Baseline	Day 21	P-value	Baseline	Day 21	P-value
NOx (μmol/l)	31 (25)	38 (25)	0.01	18.5 (13)	38.2 (25)	0.01	25.4 (21)	38.1 (24)	0.0008
hs-CRP (mg/l)	9.9 (16)	2.7 (1.8)	0.1	6.0 (6.5)	2.4 (1.7)	0.02	8.0 (12.2)	2.5 (1.7)	0.02
IL-6 (pg/ml)	1.2 (1.3)	0.6 (0.4)	0.04	0.45 (0.42)	0.13 (0.12)	0.05	0.98 (1.2)	0.41 (0.42)	0.01
VEGF (pg/ml)	451 (345)	287 (305)	0.05	260 (140)	230 (160)	0.4	364 (283)	262 (246)	0.04
VCAM1 (ng/ml)	1335 (718)	1291 (660)	0.6	609 (255)	523 (152)	0.4	1098 (703)	1087 (647)	0.9
TF (pg/ml)	165 (78)	156 (110)	0.7	307 (73)	271 (128)	0.3	195 (96)	180 (121)	0.4

Data are presented as mean (SD).